MX2018010971A - Compuestos y métodos para modular la tirosina cinasa de bruton. - Google Patents
Compuestos y métodos para modular la tirosina cinasa de bruton.Info
- Publication number
- MX2018010971A MX2018010971A MX2018010971A MX2018010971A MX2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A
- Authority
- MX
- Mexico
- Prior art keywords
- bruton
- modulating
- compounds
- methods
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
En la presente se proporcionan, entre otros, compuestos y métodos para modular la tirosina cinasa de Bruton.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307399P | 2016-03-11 | 2016-03-11 | |
US201662342004P | 2016-05-26 | 2016-05-26 | |
PCT/US2017/021966 WO2017156495A1 (en) | 2016-03-11 | 2017-03-10 | Compounds and methods for modulating bruton's tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010971A true MX2018010971A (es) | 2019-03-28 |
Family
ID=59789888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010971A MX2018010971A (es) | 2016-03-11 | 2017-03-10 | Compuestos y métodos para modular la tirosina cinasa de bruton. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10870652B2 (es) |
EP (1) | EP3426637B1 (es) |
JP (1) | JP6972002B2 (es) |
KR (1) | KR102416971B1 (es) |
CN (2) | CN109071455B (es) |
AU (1) | AU2017230098B2 (es) |
CA (1) | CA3017567A1 (es) |
ES (1) | ES2912465T3 (es) |
IL (1) | IL261583A (es) |
MX (1) | MX2018010971A (es) |
PL (1) | PL3426637T3 (es) |
WO (1) | WO2017156495A1 (es) |
ZA (1) | ZA201805951B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11554118B2 (en) | 2017-03-22 | 2023-01-17 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102416971B1 (ko) * | 2016-03-11 | 2022-07-04 | 엔젤 파마슈티칼 컴퍼니, 리미티드 | 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 |
JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
KR102384924B1 (ko) * | 2017-07-12 | 2022-04-08 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
CN108191871B (zh) * | 2018-01-02 | 2020-02-18 | 成都倍特药业有限公司 | 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用 |
TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN111662232B (zh) * | 2019-03-06 | 2022-08-02 | 中国科学院上海药物研究所 | 具有2h-吲唑结构的小分子化合物及其合成和应用 |
CA3133004A1 (en) | 2019-05-31 | 2020-12-03 | Sichuan Haisco Pharmaceutical Co., Ltd. | Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
WO2020252397A1 (en) * | 2019-06-12 | 2020-12-17 | Baylor College Of Medicine | Small molecule proteolysis-targeting chimeras and methods of use thereof |
WO2021057893A1 (zh) * | 2019-09-26 | 2021-04-01 | 南京明德新药研发有限公司 | 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物 |
WO2022253250A1 (zh) * | 2021-06-01 | 2022-12-08 | 正大天晴药业集团股份有限公司 | 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 |
WO2023009785A1 (en) * | 2021-07-29 | 2023-02-02 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2266960B1 (en) | 1999-03-26 | 2014-01-22 | Euro-Celtique S.A. | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
RU2442778C9 (ru) * | 2005-12-13 | 2012-08-10 | Шеринг Корпорейшн | Новые соединения, действующие как ингибиторы erk |
US7659283B2 (en) | 2006-02-14 | 2010-02-09 | Vertex Pharmaceuticals Incorporated | Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases |
SI2530083T1 (sl) | 2006-09-22 | 2016-09-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
US8809273B2 (en) * | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
WO2009143051A1 (en) * | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
EP2328895B1 (en) | 2008-09-16 | 2013-03-27 | Proximagen Limited | Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
KR101301533B1 (ko) | 2010-02-09 | 2013-09-04 | 한미사이언스 주식회사 | 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체 |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US9458162B2 (en) | 2012-01-31 | 2016-10-04 | Nanjing Allgen Pharma Co. Ltd. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
EP3060218A4 (en) | 2013-10-25 | 2017-07-19 | Pharmacyclics LLC | Methods of treating and preventing graft versus host disease |
WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
CA3008653A1 (en) * | 2015-10-14 | 2017-04-20 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
MX2018008815A (es) * | 2016-01-21 | 2019-03-28 | Zibo Biopolar Changsheng Pharmaceutical Co Ltd | Inhibidores de tirosina quinasa de bruton. |
KR102416971B1 (ko) * | 2016-03-11 | 2022-07-04 | 엔젤 파마슈티칼 컴퍼니, 리미티드 | 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 |
-
2017
- 2017-03-10 KR KR1020187029381A patent/KR102416971B1/ko active IP Right Grant
- 2017-03-10 CA CA3017567A patent/CA3017567A1/en active Pending
- 2017-03-10 CN CN201780028799.7A patent/CN109071455B/zh active Active
- 2017-03-10 ES ES17764260T patent/ES2912465T3/es active Active
- 2017-03-10 CN CN202210903642.7A patent/CN115746000A/zh active Pending
- 2017-03-10 US US16/083,409 patent/US10870652B2/en active Active
- 2017-03-10 EP EP17764260.0A patent/EP3426637B1/en active Active
- 2017-03-10 WO PCT/US2017/021966 patent/WO2017156495A1/en active Application Filing
- 2017-03-10 JP JP2018547964A patent/JP6972002B2/ja active Active
- 2017-03-10 AU AU2017230098A patent/AU2017230098B2/en active Active
- 2017-03-10 MX MX2018010971A patent/MX2018010971A/es unknown
- 2017-03-10 PL PL17764260T patent/PL3426637T3/pl unknown
-
2018
- 2018-09-04 IL IL261583A patent/IL261583A/en unknown
- 2018-09-05 ZA ZA2018/05951A patent/ZA201805951B/en unknown
-
2020
- 2020-08-27 US US17/004,943 patent/US11306099B1/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11554118B2 (en) | 2017-03-22 | 2023-01-17 | Xibin Liao | Bruton's tyrosine kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP3426637A4 (en) | 2019-09-18 |
US20190106423A1 (en) | 2019-04-11 |
JP2019507793A (ja) | 2019-03-22 |
JP6972002B2 (ja) | 2021-11-24 |
US11306099B1 (en) | 2022-04-19 |
US10870652B2 (en) | 2020-12-22 |
CN109071455B (zh) | 2022-08-02 |
PL3426637T3 (pl) | 2022-05-30 |
WO2017156495A1 (en) | 2017-09-14 |
ZA201805951B (en) | 2020-12-23 |
CN115746000A (zh) | 2023-03-07 |
KR20180133415A (ko) | 2018-12-14 |
AU2017230098A1 (en) | 2018-09-20 |
EP3426637B1 (en) | 2022-02-09 |
EP3426637A1 (en) | 2019-01-16 |
IL261583A (en) | 2018-10-31 |
WO2017156495A8 (en) | 2018-09-27 |
ES2912465T3 (es) | 2022-05-26 |
KR102416971B1 (ko) | 2022-07-04 |
CN109071455A (zh) | 2018-12-21 |
CA3017567A1 (en) | 2017-09-14 |
AU2017230098B2 (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010971A (es) | Compuestos y métodos para modular la tirosina cinasa de bruton. | |
MX2019005076A (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2. | |
EA201992497A1 (ru) | МОДУЛЯТОРЫ K-Ras | |
MX2021006237A (es) | Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2019007021A (es) | Anticuerpos il-11ra. | |
MX2019007020A (es) | Anticuerpos il-11. | |
MX2018008815A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
MY191581A (en) | Anti-pd-1 antibodies | |
AU2018258581A8 (en) | RAF-degrading conjugate compounds | |
EP3414234A4 (en) | BRUTON TYROSINE KINASE HEMMER | |
SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
PH12018502233A1 (en) | ErbB INHIBITORS AND USES THEREOF | |
SG11201811429XA (en) | Flow reactor | |
PH12021550413A1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2021003159A (es) | Microemulsiones que contienen antioxidantes. | |
MX2020006398A (es) | Compuestos y composiciones para tratar la fibrosis. | |
MX2019014475A (es) | Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas. | |
MX2019009199A (es) | Composiciones y métodos para modular ppp2r1a. |